• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.52% Nasdaq Up0.13%

    BG Medicine, Inc. (BGMD)

    0.22 Up 0.02(8.53%) 12:42PM EDT
    ProfileGet Profile for:
    BG Medicine, Inc.
    303 Wyman Street
    Suite 300
    Waltham, MA 02451
    United States - Map
    Phone: 781-890-1199
    Fax: 781-895-1119
    Website: http://www.bg-medicine.com

    Index Membership:N/A
    Industry:Medical Laboratories & Research
    Full Time Employees:5

    Business Summary 

    BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on BG Medicine, Inc.

    Corporate Governance 
    BG Medicine, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 7; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Paul R. Sohmer M.D., 67
    Chief Exec. Officer, Pres and Director
    Mr. Stephen P. Hall , 65
    Chief Financial Officer, Principal Accounting Officer, Exec. VP and Treasurer
    Dr. Aram Adourian Ph.D., 46
    Chief Scientific Officer
    Dr. Noubar B. Afeyan Ph.D., 53
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders